Entry Detail


General Information

Database ID: LDA0005697
Species: Homo sapiens
Confidence Score: 0.985791
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:PVT1
Full Name:Pvt1 oncogene
Category:LncRNA
Species:Homo sapiens
Synonyms:LINC00079|MIR1204HG|NCRNA00079|TP53LC09|onco-lncRNA-100
Chromosome:8
Strand:+
Coordinate:
Start Site(bp):127794533End Site(bp):128101253
External Links:
Ensembl ID:ENSG00000249859
Ensembl Transcript ID:N/A
Entrez Gene:5820.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:128   
More Information
Causal Disease Number:100
Network:
Top Causal Diseases:
Osteosarcoma  (Score: 1)
Carcinoma, Renal Cell  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Prostatic Neoplasms  (Score: 1)
Stomach Neoplasms  (Score: 1)
Breast Neoplasms  (Score: 1)
Carcinoma, Non-Small-Cell Lung  (Score: 1)
Uterine Cervical Neoplasms  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Carcinoma, Renal Cell  (Score: 1)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:1936D050197
Disease Name:atherosclerosisAtherosclerosis
Category:Disease OntologyMeSH
Type:Cardiovascular Diseases
Define:A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
Alias:Atherosclerosis//Atheroscleroses//Atherogenesis//Atherogeneses

 

Disease Association Statistics

Total Associated ncRNA Number:206   
More Information
Causal ncRNA Number:96
Network:
Top Causal ncRNAs:
XIST  (Score: 0.999893)
H19  (Score: 0.999893)
XIST  (Score: 0.999893)
H19  (Score: 0.999893)
MIAT  (Score: 0.985791)
TUG1  (Score: 0.985791)
MIAT  (Score: 0.985791)
PVT1  (Score: 0.985791)
TUG1  (Score: 0.985791)
PVT1  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:RNA Pull-Down//IHC//Western Blot//Transfection//Flow Cytometry//qRT-PCR//CCK8//MTT//Luciferase Report Assay//ELISA//Colony Formation Assay//EdU Staining
Weak Evidence:

 

Reference

[1] PubMed ID:34775377
Disease Name:Atherosclerosis
Sample:AS patients
Dysfunction Pattern:Regulation(MAPK/NF-κB pathway)
Validated Method:Western Blot//Transfection//Colony Formation Assay//Flow Cytometry//qRT-PCR//MTT//ELISA//IHC//EdU Staining
Description:Consequently, PVT1 was highly expressed in AS patients. Briefly, silencing PVT1 inhibited AS development by downregulating MAPK/NF-κB pathway.
Causality:Yes
Causal Description:Silencing PVT1 decreased levels of TG, TC, LDL, IL-6, IL-1β, TNF-α, MMP-2, MMP-9, CRP, TIMP-1, MAPK, and NF-κB, increased HDL, reduced atherosclerotic plaques and macrophage content in mice, inhibited viability, clones and EdU positive rates in HA-VSMCs, but promoted apoptosis and cell cycle arrest. Inhibition of MAPK/NF-κB pathway suppressed proliferation and promoted apoptosis of HA-VSMCs while PVT1 overexpression facilitated AS development.
Clinical-realted Application:

[2] PubMed ID:35038974
Disease Name:Atherosclerosis
Sample:AS patients and HUVECs
Dysfunction Pattern:Interaction(miR-30 c-5p)
Validated Method:RNA Pull-Down//Western Blot//Transfection//CCK8//qRT-PCR//Flow Cytometry//Luciferase Report Assay//ELISA
Description:lncRNA PVT1 was overexpressed in the serum of AS patients and in ox-LDL-stimulated HUVECs relative to controls. Moreover, miR-30 c-5p was verified as a direct target of lncRNA PVT1. Furthermore, we observed that miR-30 c-5p expression was lower in AS patients than in controls. In addition, the influence of lncRNA PVT1 knockdown on ox-LDL-treated HUVECs was significantly reversed by downregulation of miR-30 c-5p.
Causality:Yes
Causal Description: Knockdown of lncRNA PVT1 facilitated proliferation, reduced apoptosis, and secretion of inflammatory factors in ox-LDL-treated HUVECs.
Clinical-realted Application: